AXSM Stock Catapults After Winning A 60-Year First In Depression Treatment | Investor's Business Daily - Investor's Business Daily

Axsome's drug targets a neurotransmitter believed to play a role in depression.

The Food and Drug Administration approved a new depression treatment from Axsome Therapeutics (AXSM), leading AXSM stock to catapult higher on Friday. XOn today's stock market, shares soared 40.4% t… [+2073 chars]

full article...